Results 41 to 50 of about 2,643,317 (205)

De novo UBE2A mutations are recurrently acquired during chronic myeloid leukemia progression and interfere with myeloid differentiation pathways

open access: yesHaematologica, 2019
Despite the advent of tyrosine kinase inhibitors, a proportion of chronic myeloid leukemia patients in chronic phase fail to respond to imatinib or to second-generation inhibitors and progress to blast crisis. Until now, improvements in the understanding
Vera Magistroni   +27 more
doaj   +1 more source

Recurrent ETNK1 mutations in atypical chronic myeloid leukemia [PDF]

open access: yesBlood, 2015
Key PointsWhole-exome sequencing reveals the presence of recurrent somatic mutations of ETNK1 in patients with atypical chronic myeloid leukemia. ETNK1 mutations impair the catalytic activity of the enzyme, causing a decrease in the intracellular levels of phosphoethanolamine.
Gambacorti Passerini CB   +31 more
openaire   +4 more sources

Eradication of chronic myeloid leukemia stem cells: a novel mathematical model predicts no therapeutic benefit of adding G-CSF to imatinib [PDF]

open access: yes, 2009
Imatinib mesylate induces complete cytogenetic responses in patients with chronic myeloid leukemia (CML), yet many patients have detectable BCR-ABL transcripts in peripheral blood even after prolonged therapy.
Holyoake, T.   +14 more
core   +2 more sources

Inhibition of MDR1 does not sensitize primitive chronic myeloid leukemia CD34+ cells to imatinib [PDF]

open access: yes, 2009
<p><b>Objective:</b> To investigate the interaction of imatinib mesylate (IM) with the clinically relevant adenosine triphosphate-binding cassette efflux transporter MDR1 (ABCB1) in cells from patients with chronic myeloid leukemia (CML)
Holyoake, T.L.   +9 more
core   +1 more source

Transformation of secondary myelodysplastic syndrome to atypical chronic myeloid leukemia in a female patient with acute myeloid leukemia [PDF]

open access: yesТерапевтический архив, 2016
Secondary myeloid neoplasia may be a complication of intensive cytostatic therapy. The most common types of secondary neoplasias are acute myeloid leukemia and myelodysplastic syndrome. The development of secondary atypical chronic myeloid leukemia (aCML)
S V Gritsaev   +9 more
doaj  

Bcr/Abl Interferes with the Fanconi Anemia/BRCA Pathway: Implications in the Chromosomal Instability of Chronic Myeloid Leukemia Cells [PDF]

open access: yes, 2010
Chronic myeloid leukemia (CML) is a malignant clonal disorder of the hematopoietic system caused by the expression of the BCR/ABL fusion oncogene. Although it is well known that CML cells are genetically unstable, the mechanisms accounting for this ...
Valeri, Antonio   +71 more
core   +2 more sources

Atypical presentation of chronic myeloid leukemia with visual disturbance

open access: yesJournal of Dr. NTR University of Health Sciences, 2018
Chronic myeloid leukemia (CML) is a clonal hematopoietic disorder characterized by a reciprocal translocation between chromosome 9 and 22 resulting in bcr-abl1 fusion gene.
Rachana Chennamaneni   +3 more
doaj   +1 more source

Treatment of Ph-positive Chronic Myeloid Leukemia with alpha-Interferon (Roferon-A). The Italian Cooperative Study Group experience.

open access: yes, 1993
This is an interim report of two National studies of human recombinant interferon-alpha 2a (ROFERON-A) in Ph+ chronic myeloid leukemia (CML). The first study (1986-1988) enrolled 322 patients who were randomized to treatment by IFN or by hydroxyurea ...
The Italian Cooperative Study Group on Chronic Myeloid Leukemia   +3 more
core   +1 more source

Direct evidence that leukemic cells present HLA-associated immunogenic peptides derived from the BCR-ABL b3a2 fusion protein [PDF]

open access: yes, 2001
The BCR-ABL oncogene is central in the pathogenesis of chronic myeloid leukemia (CML). Here, tandem nanospray mass spectrometry was used to demonstrate cell surface HLA- associated expression of the BCR-ABL peptide KQSSKALQR on class I-negative CIVIL ...
Lill, JR   +14 more
core   +1 more source

Dasatinib for the treatment of chronic myeloid leukemia: patient selection and special considerations [PDF]

open access: yes, 2016
Dilek Keskin, Sevil Sadri, Ahmet Emre Eskazan Department of Internal Medicine, Division of Hematology, Cerrahpasa Faculty of Medicine, Istanbul University, Istanbul, Turkey Abstract: Dasatinib is one of the second-generation tyrosine kinase inhibitors
Sadri S   +5 more
core   +1 more source

Home - About - Disclaimer - Privacy